Survey on the Application of Adjuvant Therapy in Completely Resected Non-Small Cell Lung Cancer Patients

YANG Xue-ning,YAN Hong-hong,ZHONG Wen-zhao,WU Yi-long

DOI: https://doi.org/10.3969/j.issn.1671-5144.2009.04.025

2009-01-01

Abstract:Objectives We conducted a survey to assess and compare Chinese physicians' practice of adjuvant therapy in completely resected non-small cell lung cancer (NSCLC) patients against the evidence-based guidelines. Methods On May 16,2009,130 Chinese physicians who attended a national NSCLC symposium were surveyed. The survey questionnaire included physician's demographics and adjuvant therapy questions. Results 120 valid questionnaires were returned (92.31%). Cisplatin is the platinum of choice (80.67%). The most commonly combined drugs are Gemcitabine (50.42% ),Vinorelbin (37.82% ),Docetaxel (33.61% )and Paclitaxel (19.33% ). 4 cycles is the mostly selected. The choosing of adjuvant radiotherapy in stage ⅢA(N2),adjuvant chemotherapy in Stage ⅠB and elderly patients(>75 years old) are 77.59%,68.07% and 33.61% respectively. 33.33% of physicians selected adjuvant targeted therapy for adenocarcinoma. Conclusions The practice of adjuvant chemotherapy in NSCLC is in agreement with current evidence-based guideline; howevers,there is tendency of overtreatment in stage ⅠB and ⅢA(N2) patients.